FDA Approves Rinvoq for Moderate to Severe Rheumatoid Arthritis - Managed Care magazine

FDA Approves Rinvoq for Moderate to Severe Rheumatoid Arthritis  Managed Care magazine

The FDA has approved Rinvoq (upadacitinib), a 15-mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active ...